Live
FierceBiotechKailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assetsFierceBiotechFDA urges clinical trial sponsors to report the results of their studiesEndpoints NewsWhite House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO saysThermo FisherThermo Fisher Scientific (TMO) Valuation Check As New PRECISE Collaboration Targets Long Term Precision Medicine Growth - simplywall.stEndpoints NewsFDA narrows in on search for new biologics and vaccines leaderBioPharma DiveSpyre drug for inflammatory bowel disease shows promise in early studyBioPharma DiveAllogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaFierceBiotechBeyond the Hype: Turning NAMs into Actionable EvidenceFierceBiotechRevolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trialFierceBiotechAbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assetsFierceBiotechSpyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s EntyvioBioWorldAppointments and advancements for April 13, 2026
BioPharma Dive Apr 13, 2026

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Original
Body unavailable. Use the original source.

Directory

59 All